Skip to content
Menu

PolyPid Ltd. PYPD

Full chart Compare
Set alert

Price alert · PYPD

All alert types
6.55 USD -0.01 (-0.15%)

Regular-session close

7.13 +0.58 +8.87%

Pre-market · Nov 20, 4:35 AM ET

6.40 Day range 7.25
3.50 52-week range 7.25
YTD
+50.92%
1 year
+80.44%

5D -0.05 (-0.76%)

66.256.506.75ThuFriMonTueWed6.56
Market cap
138.37M
EPS (ttm)
-1.31
Shares out
6.80M
Forward P/E
-1.36
YTD return
+50.92%
1-year return
+80.44%
50-day average
3.28
200-day average
3.90
Enterprise value
18.09M
Volume
451.65K
Avg volume
138.56K
Open
6.75
Previous close
6.56
Day's range
6.40 – 7.25
52-week range
3.50 – 7.25
Beta
1.32
Analysts
Buy
Price target
11.75 (+79.4%)

Key statistics

Free cash flow
-9.82M
Total cash
9.35M
Total debt
11.03M
Return on equity
-496.62%
Short % of float
0.28%

Fundamental scorecard

4 of 25 checks passed on PYPD’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
PYPD Revenue — quarterly 0
PYPD Net income — quarterly -9.98M
PYPD EPS — quarterly -0.78

Earnings

PYPD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 12, 2025Dec 1, 2024-1.05———
Nov 13, 2024Sep 1, 2024-1.07-1.22-0.15-14.02%
Aug 14, 2024Jun 1, 2024-1.51-1.25+0.26+17.22%
Aug 14, 2024Jun 1, 2024-1.51———
May 8, 2024Mar 1, 2024-1.96-1.37+0.59+30.10%
May 8, 2024Mar 1, 2024-1.96———

Upgrades / downgrades

PYPD analyst upgrades and downgrades
DateFirmActionFromTo
Dec 16, 2024HC Wainwright & Co.reitBuyBuy
Nov 4, 2024Craig-Halluminit—Buy
Oct 2, 2024HC Wainwright & Co.reitBuyBuy
Aug 15, 2024HC Wainwright & Co.reitBuyBuy
Jun 18, 2024HC Wainwright & Co.reitBuyBuy
May 9, 2024HC Wainwright & Co.reitBuyBuy

About PolyPid Ltd.

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
polypid.com

News

Your note

Sign in to keep a note on PYPD — it syncs with the Stock Master app.

Institution ownership

PYPD institution ownership
Holder% heldSharesValueReported
AIGH Capital Management LLC9.99%679,6682.50MSep 29, 2024
Rosalind Advisors, Inc.9.98%679,1682.50MSep 29, 2024
DAFNA Capital Management, LLC4.53%308,4971.14MSep 29, 2024
Stonepine Capital Management, LLC2.04%138,504509.69KSep 29, 2024
Adar1 Capital Management, LLC 1.38%93,902345.56KSep 29, 2024
Yelin Lapidot Holdings Management Ltd.0.16%11,15341.04KSep 29, 2024

Fund ownership

PYPD fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.00%80294Oct 30, 2024